Gunshot Injuries Treatment Market - By Size, Share, Emerging Trends, Analysis and Forecast from 2019 till 2027

The Global Gunshot Injuries Treatment Market was valued at US$ 6.9 million in 2015 and is projected to exhibit a CAGR of 8.2% over the forecast period (2017-2025), as highlighted in a new report published by Coherent Market Insights. Technological developments such as innovative pocket sized device, which use tiny sponges and emergency treatment in the battlefield for soldiers, are expected to be major factors driving growth of the global gunshot injuries treatment market over the foreseeable future.
Efficient treatment by products that prevent postpartum hemorrhage to boost the gunshot injuries treatment market
Postpartum hemorrhage (PPH) is the leading cause of maternal mortality in low-income countries, and responsible for a quarter of all maternal deaths globally. According to an article published by Medscape, pregnancy-related mortality ratio was estimated to be 17.3 deaths per 100,000 pregnant women, with around 11.4% of these deaths caused due by postpartum hemorrhage, in 2013. The initiatives taken by organizations such as the United States Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, and the UK Government to aid research for the development of preventive devices for PPH is a major factor causing expansion of the gunshot injuries treatment market. Furthermore, the development of the XSTAT-PPH device by Oregon Health & Science Univsersity and RevMedx for the treatment of postpartum hemorrhage (PPH) in low resource settings accelerates growth of the gunshot injuries treatment market.
The gunshot wounds sustained on the battlefield are caused by military ammunition and have a greater potential to destroy the affected tissues. Hemorrhage control, prevention and reconstruction of infection are the surgical priorities for management of gunshot injuries. According to an article published in Current Reviews in Musculoskeletal Medicine, in 2015, around 70% of battlefield wounds sustained in conflict since the Second World War were gunshot injuries during the early phases of conflicts. Soldiers require transfer to a trauma center for definitive management, as the initial care and stabilization is carried out in the emergency department. The Xstat syringe was the only FDA-approved device for immediate treatment of blood flow.
Key takeaways of the Gunshot Injuries Treatment Market:
• The global gunshot injuries treatment market is expected to exhibit a CAGR of 8.2% over the forecast period, with economies in Asia Pacific, Latin America, Middle East, and Africa focusing on increasing their military spending.
• The Xstat is the dominant product segment in the market, as this portable device provides emergency treatment for soldiers in the battlefield
• RevMedx, Inc currently is the only player involved in the global gunshot injuries treatment market.